CA2323936A1 - Estrogen receptor - Google Patents
Estrogen receptor Download PDFInfo
- Publication number
- CA2323936A1 CA2323936A1 CA002323936A CA2323936A CA2323936A1 CA 2323936 A1 CA2323936 A1 CA 2323936A1 CA 002323936 A CA002323936 A CA 002323936A CA 2323936 A CA2323936 A CA 2323936A CA 2323936 A1 CA2323936 A1 CA 2323936A1
- Authority
- CA
- Canada
- Prior art keywords
- estrogen receptor
- ligand
- present
- isolated
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010038795 estrogen receptors Proteins 0.000 title claims abstract description 114
- 102000015694 estrogen receptors Human genes 0.000 title claims abstract description 113
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 61
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 61
- 239000002157 polynucleotide Substances 0.000 claims abstract description 61
- 239000003446 ligand Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 230000001404 mediated effect Effects 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000006386 Bone Resorption Diseases 0.000 claims abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 5
- 230000002159 abnormal effect Effects 0.000 claims abstract description 5
- 230000024279 bone resorption Effects 0.000 claims abstract description 5
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 11
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 230000004568 DNA-binding Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 11
- 108020003175 receptors Proteins 0.000 abstract description 11
- 201000011529 cardiovascular cancer Diseases 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 20
- 108091026890 Coding region Proteins 0.000 description 16
- 239000012634 fragment Substances 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 1
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- -1 inverse agonist Substances 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying ligands which bind to this receptor, to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions, such as abnormal bone resorption, cardiovascular diseases, cancer, or central nervous system disorders.
Description
TITLE OF THE INVENTION
ESTROGEN RECEPTOR
FIELD OF THE INVENTION
This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying l.igands which bind to this receptor, to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions.
BACKGROUND OF THE INVENTION
This Application is a Divisional of Canadian Patent Application, Serial No. 2,302,629, filed September 4, 1998.
Nuclear receptors are a large class of proteins that are.
responsible for the regulation of complex cellular events including cell differentiation,homeostasis, the growth and functioning of various organs and tissues, and transcription. It is believed that nuclear receptors function by transducing extracellular chemical signals from hormones into a transcriptiona:L response.
Estrogen receptors are a subclass of the larger nuclear receptor class. The estrogen receptors are proteins that are responsive to estrogen and estrogen-like molecules. Estrogen receptors are believed to play an important role in the mammalian endocrine system, the reproductive organs, breast tissue, bone tissue, and the vascular system, and are believed to be involbed in the development and progression of various diseases states such as abnormal bone resorption, cardiovascular disease, cancer, and central nervous system disorders. It is believed that various disease states and conditions can be treated or prevented by the development of appropriate ligands, i.e. drugs, for modifying the activity of estrogen receptors. Consequently there is a neeed to identify estrogen receptors and their mode of action and to also identify ligands for modifying the action of these receptors.
At least two distinct types of estrogen receptors have been reported. An estrogen receptor having 595 amino acids is disclosed in S Green, S. et al., Nature, 320, pp. 134-139 (1986) and Greene, G.L. et al., Science, 231, pp.1I50-1154 (1986), These references also disclose the corresponding DNA sequences for the receptor.
The other reported type of estrogen receptor has been disclosed by two research groups and has been designated "(3" (beta). One research group discloses a 485 amino acid (3 receptor that is obtained from rat, human, and mouse sources, as well as the corresponding DNA
sequences. See PCT application No. W0 97/09348, to Kuiper, G.G. J. M.
et al., published March 13, 1997, The second research group discloses a similar estrogen receptor containing 483 amino acids. The corresponding DNA
sequence is also disclosed. See Mosselman. S. et al., ER/3: identification and characterization of a nouel human estrogen receptor, FEBS Letters, 392, pp. 49-53 (1996), In the present invention, a novel estrogen receptor having 548 amino acid units, and thai is distinct from the disclosed 595 amino acid, 485 amino acid, and 483 amino acid estrogen receptors, has been identified and isolated from human tissue. It is believed that this novel 2S estrogen receptor plays a key role in mammalian physiology. This novel estrogen receptor is an important research tool for identifying and designing ligands for use in pharmaceutical compositions for treating and/or preventing a wide range of estrogen receptor mediated diseases or conditions.
It is therefore an object of the present invention to provide a novel isolated estrogen receptor.
It is another object of the present invention to provide the amino acid sequence of a novel estrogen receptor.
It is another object of the present invention to provide the 3S polynucleotide sequence encoding a novel estrogen receptor.
ESTROGEN RECEPTOR
FIELD OF THE INVENTION
This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying l.igands which bind to this receptor, to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions.
BACKGROUND OF THE INVENTION
This Application is a Divisional of Canadian Patent Application, Serial No. 2,302,629, filed September 4, 1998.
Nuclear receptors are a large class of proteins that are.
responsible for the regulation of complex cellular events including cell differentiation,homeostasis, the growth and functioning of various organs and tissues, and transcription. It is believed that nuclear receptors function by transducing extracellular chemical signals from hormones into a transcriptiona:L response.
Estrogen receptors are a subclass of the larger nuclear receptor class. The estrogen receptors are proteins that are responsive to estrogen and estrogen-like molecules. Estrogen receptors are believed to play an important role in the mammalian endocrine system, the reproductive organs, breast tissue, bone tissue, and the vascular system, and are believed to be involbed in the development and progression of various diseases states such as abnormal bone resorption, cardiovascular disease, cancer, and central nervous system disorders. It is believed that various disease states and conditions can be treated or prevented by the development of appropriate ligands, i.e. drugs, for modifying the activity of estrogen receptors. Consequently there is a neeed to identify estrogen receptors and their mode of action and to also identify ligands for modifying the action of these receptors.
At least two distinct types of estrogen receptors have been reported. An estrogen receptor having 595 amino acids is disclosed in S Green, S. et al., Nature, 320, pp. 134-139 (1986) and Greene, G.L. et al., Science, 231, pp.1I50-1154 (1986), These references also disclose the corresponding DNA sequences for the receptor.
The other reported type of estrogen receptor has been disclosed by two research groups and has been designated "(3" (beta). One research group discloses a 485 amino acid (3 receptor that is obtained from rat, human, and mouse sources, as well as the corresponding DNA
sequences. See PCT application No. W0 97/09348, to Kuiper, G.G. J. M.
et al., published March 13, 1997, The second research group discloses a similar estrogen receptor containing 483 amino acids. The corresponding DNA
sequence is also disclosed. See Mosselman. S. et al., ER/3: identification and characterization of a nouel human estrogen receptor, FEBS Letters, 392, pp. 49-53 (1996), In the present invention, a novel estrogen receptor having 548 amino acid units, and thai is distinct from the disclosed 595 amino acid, 485 amino acid, and 483 amino acid estrogen receptors, has been identified and isolated from human tissue. It is believed that this novel 2S estrogen receptor plays a key role in mammalian physiology. This novel estrogen receptor is an important research tool for identifying and designing ligands for use in pharmaceutical compositions for treating and/or preventing a wide range of estrogen receptor mediated diseases or conditions.
It is therefore an object of the present invention to provide a novel isolated estrogen receptor.
It is another object of the present invention to provide the amino acid sequence of a novel estrogen receptor.
It is another object of the present invention to provide the 3S polynucleotide sequence encoding a novel estrogen receptor.
CA 02323936 2000-11-20, WO 99/t2961 PCTNS98/18577 It is another object of the present invention to provide methods for isolating a novel estrogen receptor.
It is another object of the present invention to provide ligands capable of binding to a novel estrogen receptor.
5 It is another object of the present invention to provide pharmaceutical compositions comprising ligands capable of binding to a novel estrogen receptor.
It is another object of the present invention to provide methods for treating and/or preventing estrogen receptor mediated diseases or 10 conditions.
These and other objects will become readily apparent from the detailed description which follows.
SUMMARY OF THE INVENTION
15 The present invention relates to an isolated estrogen receptor .
comprising the amino acid sequence of Figure 1 (which also corresponds to SEQ ID NO: 1 ).
In further embodiments, the present invention relates to an isolated estrogen receptor having an amino acid sequence that is 20 substantially similar to the amino acid sequence of Figure 1, wherein the estrogen receptor comprises at least 531 amino acids.
In further embodiments, the present invention relates to an isolated estrogen receptor comprising at least-531 amino acids and having substantially the same ligand binding properties or substantially 25 the same DNA binding properties as the estrogen receptor of Figure 1.
In further embodiments, the present invention relates to an isolated estrogen receptor that is derived from mammalian cells, preferably human cells.
In further embodiments, the present invention relates to an 30 isolated polynucleotide encoding the estrogen receptor having the amino acid sequence of Figure 1.
In further embodiments, the present invention relates to an isolated polynucleotide which is a DNA, a cDNA, or an RNA.
In further embodiments, the present invention relates to an 35 isolated polynucleotide which hydridizes to and is complementary to the CA 02323936 2000-11-20 ' a-WO 99112961 PCTlUS98I18577 polynucleotide encoding the estrogen receptor having the amino acid sequence of Figure 1.
In further embodiments, the present im~ention relates to an isolated polynucleotide comprising a polynucleotide encoding a mature polypeptide encoded by the estrogen receptor polynucleotide contained in an ATCC Deposit selected from the group consisting of ATCC Deposit No. 209238, ATCC Deposit No. 209239, and ATCC Deposit No. 209240.
In further embodiments, the present invention relates to an isolated polynucleotide comprising the nucleotide sequence of Figure 2 (which also corresponds to SEQ ID NO: 2).
In further embodiments, the present invention relates to an isolated polynucleotide which hybridizes to and is complementary to the polynucleotide of Figure 2, wherein said polynucleotide comprises at least 1593 nucleotides.
In further embodiments, the present invention relates to a vector containing the DNA.
In further embodiments, the present invention relates to a host cell transformed or transfected with the vector of the present invention.
In further embodiments, the present invention relates to a method for producing an estrogen receptor of the present invention.
In Further embodiments, the present invention relates to a method for determining whether a ligand can bind to the estrogen receptor of the present invention.
In further embodiments, the present invention relates to a ligand detected by the methods of the present invention.
In further embodiments, the present invention relates to a pharmaceutical composition comprising a ligand of the present invention.
In further embodiments, the present invention relates to a method for treating or preventing an estrogen receptor mediated disease or condition by administering an effective amount of a pharmaceutical composition of the present invention.
The deposits referred to herein will be maintained under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure. These deposits are provided merely as a convenience, The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, - are controlling in the event of any conflict with the description of the sequences herein. A
license may be required to make, use or sell the deposited materials, and no such license is hereby granted.
All percentages and ratios used herein, unless otherwise indicated, are by weight. The invention hereof can comprise, consist of, or consist essentially of the essential as well as optional ingredients, components, and methods described herein.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 shows the amino acid sequence of the estrogen receptor, i.e. the polypeptide, of the present invention.
FIG. 2 shows the nucleotide sequence, i.e. the cDNA
polynucleotide, encoding the estrogen receptor of the present invention.
This sequence includes the translation termination codon "TGA".
DESCRIPTION OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a polypeptide, namely an estrogen receptor, which has the deduced amino acid sequence of FIG. 1 or which has the amino acid sequence encoded by the cDNA of the clone deposited as ATCC Deposit No. 209238 on September 8, 1997, by the genomic DNA of the clone deposited as ATCC Deposit No. 209239 on September 8,1997, or by the genomic DNA of the clone deposited as ATCC Deposit No. 209240 on September 8, 1997. The present invention also relates to fragments, analogs and derivatives of such an estrogen receptor.
The terms "fragments", "derivatives", and "analogs " when referring to the estrogen receptor of FIG. 1 or that encoded by the deposited DNA, means a polypeptide which retains essentially the same biological function or activity as such estrogen receptor. Thus, an i analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature estrogen receptor.
The estrogen receptor of the present invention can be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide of the sequence of FIG. 1, or of that encoded by the deposited DNA. Also contemplated within the scope of the present invention are splice variants of the receptor of FIG. 1, or that encoded by the deposited DNA.
The fragments, derivatives, or analogs of the estrogen receptor of FIG. 1 or that encoded by the deposited DNA can be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue can be one that is or is not encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature estrogen receptor is fused with another compound, such as a compound to increase the half life of the estrogen receptor (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature estrogen receptor, such as a leader or secretory sequence or a sequence which is employed for purification of the mature estxogen receptor or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those sitilled in the art from the teachings herein.
The present invention also encompasses estrogen receptors which have substantially the same amino acid sequence as the estrogen receptor of Figure i. In further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 75% identical with the sequence shown in Figure 1.
In even further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 94°6 identical with the sequence shown in Figure 1. In even further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 95°.6 identical with the sequence shown in Figure 1. In even further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 99%
identical with the sequence shown in Figure 1.
The present invention also encompasses estrogen receptors comprising at least 531 amino acids and having substantially the same ligand binding proper~es or substantially the same DNA binding properties as that of the estrogen receptor of Figure 1. In other words, the respective ligand binding or DNA binding domains of the receptors have at least about 750, homology, preferably about 90°6 homology, more preferably about 95°.6 homology, and most preferably about 99°rb homology to each of the respective ligand binding and DNA binding domains in the receptor of Figure 1.
In accordance with another aspect of the present invention, there is provided an isolated nucleic acid, i.e. the polynucleotide, which encodes for the mature estrogen receptor having the deduced amino acid I S sequence of FIG. 1, or for the mature estrogen receptor encoded by the DNA of the deposited clones.
A polynucleotide encoding an estrogen receptor of the present invention can be obtained by performing polymerase chain reactions (PCR) on human testis cDNA and subcloning into a vector in JM109 E.
cola. Alternatively, the polynucleotide can be obtained by screening a human genomic DNA library derived from human testis.
The polynucleotide of the present invention can be in the form of RNA or in the form of DNA, which DNA includes eDNA, genomic DNA, and synthetic DNA. The DNA can be double-stranded or single-stranded, and if single stranded can be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature estrogen receptor can be identical to the coding sequence shown in FIG.
2 or that of the deposited clones or can be a different coding sequence, which coding sequence, as a result of redundancy or degeneracy of the genetic code, encodes the same, mature estrogen receptors as the DNA
of FIG. 2 or the deposited DNA.
The polynucleotide which encodes for the mature estrogen receptor of FIG. 1 or for the mature polypeptide encoded by the deposited DNA can include: only the coding sequence for the mature polypeptide;
the coding sequence for the mature polypeptide and additional coding _7_ sequence such as a leader or secretory sequence or a proprotein sequence; or the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequepce, such as introns or non-coding sequence ~' and/or 3' of the coding sequence for the mature polypeptide.
Thus, the term "polynucleotide encoding a polypeptide"
encompasses a polynucleotide which includes coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the polypeptide having the deduced amino acid sequence of FIG. 1 or the polypeptide encoded by the DNA of the deposited clones. The variant of the polynucleotide can be a naturally occurring allelic variant of the polynucleotide. The present invention also relates to polynucleotide probes constructed from the polynucleotide sequence of FIG. 2 or a segment of the sequence of FIG. 2 amplified by the PCR method, which can be utilized to screen a cDNA library to deduce the estrogen receptor of the present invention.
Thus, the present invention includes polynucleotides encoding the same mature estrogen receptor as shown in FIG. 1 or the same mature polypeptide encoded by the DNA of the deposited clones, as well as variants of such polynucleotides which variants encode for fragments, derivatives or analogs of the polypeptide of FIG. 2 or the polypeptide encoded by the DNA of the deposited clones. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.
As hereinabove indicated, the polynucleotide can have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in FIG. 2 or of the coding sequence of the deposited clones. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which can have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.
_g_ The present invention further relates to polynucleotides which hybridize to the polynucleotides encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 75°k complementary to the polynucleotide encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 90°~n complementary to the poiynucleotide encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 95°.~o complementary to the polynucleotide encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 99% complementary to the polynucleotide encoding the estrogen receptor I S having the amino acid sequence of FIG. 1.
The present invention relates to an isolated polynucleotide comprising at least 1593 nucleotides. The present invention relates to an isolated polynucleotide comprising at least 1593 nucleotides which hybridizes to and is at least about 75°6 complementary to the polynucleotide of FIG. 2. The present invention relates to an isolated polynucleotide comprising at least 1593 nucleotides which hybridizes to and is at least about 90°r6 complementary to the polynucleotide of FIG.
2.
The present invention relates to an isolated polynucleotide comprising at Least 1593 nucleotides which hybridizes to and is at least about 95°.b 2S complementary to the polynucleotide of FIG. 2. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 9996 complementary to the poiynucleotide of FIG. 2.
The polynucleotides which hybridize to the hereinabove described polynucleotides encode estrogen receptors which retain substantially the same biological function or activity as the mature estrogen receptors encoded by the cDNA of FIG 2 or the deposited DNA. Hybridization is described in U.S. Patent No. 5,501,969, to Hastings et al., issued March 26, 1996.
The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.
The term "isolated' means that the material is removed from its S original environment (e.g., the natural environment if it is naturally-occuring). For example, a naturally-occuring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of estrogen receptors of the invention by recombinant techniques.
Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which can be, for example, a cloning vector or an expression vector. The vector can be, for example in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified for activating promoters, selecting transformants or amplifying the estrogen receptor genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
The polynucleotide of the present invention can be employed for producing a polypeptide by recombinant techniques. Thus, for example, the polynucleotide sequence can be included in any one of a variety of expression vehicles, in particular vectors or plasmids for expressing an estrogen receptor. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40: bacterial plasmids; phage DNA; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl, pox virus, and pseudorabies. However, any other plasmid or vector can be used as long as it is replicable and viable in the host.
As hereinabove indicated the appropriate DNA sequence can be inserted into the vector by a variety of procedures. In general, the DNA
sequence is inserted into appropriate restriction endonuclease sites by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
The present invention also includes recombinant constructs comprising one or more of the sequences as broadly defined herein. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.
In a further embodiment, the present invention relates to host cells containing the above-described construct. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Deatran mediated transfection, or electroporation lDavis, L., Dibner, M., Battey, L, Basic Methods in Molecular Biology, 1986) .
The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
Alternatively, the estrogen receptors of the present invention can be synthetically produced by conventional peptide synthesizers.
ll~Iature estrogen receptors can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters.
Cell-free translation systems can also be employed to produce such estrogen receptors using R.NAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor, NY, 1989).
CA 02323936 2000-11-20.
WO 99112961 PCT/US98lt 85??
The estrogen receptors of the present invention can be naturally purified products expressed from a high expressing cell line, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by 5 bacterial, yeast, higher plant, insect and mammalian cells in culture).
Alternatively, a baculovirus~nsect cell expression system can also be employed.
The estrogen receptors, their fragments or other derivatives or analogs thereof, or cells expressing them can be used as an immunogen IO to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain and humanized antibodies, as well as Fab fragments, or the product of a Fab expression library. Various procedures known in the art can be used for the production of such I S antibodies and fragments.
The present invention is also directed to ligands, i.e. drugs, of the estrogen receptors herein. The term "ligand" as used herein means any molecule which binds to the estrogen receptor of the present invention.
These ligands can have either agonist, partial agonist, antagonist, 20 partial antagonist, inverse agonist, or mixtures of these properties.
Thus, for example, a ligand that binds to an estrogen receptor of the present invention might modify, inhibit, or eliminate its function. In this way, the ligand can be used to treat or prevent a disease in which the estrogen receptor is involved. The ligands contemplated herein are 25 those that have selectivity to specifically activate or inhibit genes that are normally regulated by the estrogen receptors of the present invention.
The present invention also relates to methods for determining whether a ligand not Down to be capable of binding to a human estrogen receptor can bind to a human estrogen receptor. These 30 methods comprise contacting a mammalian cell comprising an isolated DNA molecule encoding a human estrogen receptor with the ligand under conditions permitting binding of ligands known to bind to an estrogen receptor, detecting the presence of any of the ligand bound to a human estrogen receptor, and thereby determining whether the ligand 35 binds to a human estrogen receptor. In these methods, the mammalian I~
cell is actually expressing the isolated DNA molecules. The general methodology for conducting such a method is well known to those of ordinary skill in the art. See EP 787,797, to Weinshank et al., published July 6, 1997..
Alternatively, RNA that ultimately encodes for the estrogen receptor could be injected into, for example Xenopus oocytes, and expressed, and used in analogous assay experiments.
The present invention also relates to pharmaceutical compositions comprising the ligands of the present invention. Such compositions comprise a pharmaceutically effective amount of the ligand. The term "pharmaceutically effective amount", as used herein, means that amount of the ligand that will elicit the desired therapeutic effect or response when administered in accordance with the desired treatment regimen. The ligand is typically administered in admixture with IS suitable pharmaceutical diluents, excipients, or carriers, collectively referred to herein as "carrier materials", suitably selected with respect to the mode of administration, i.e. oral, LV., nasal, parenteral, ocular, etc. A wide variety of product and dosage forms well known to one of ordinary skill in the art ca.n be used to administer these ligands.
The present invention also relates to methods for treating and/or preventing estrogen receptor mediated diseases or conditions. By "estrogen receptor mediated diseases or conditions" is meant a physiological or pathological state in which an estrogen receptor is involved. Nonlimiting examples of estrogen receptor mediated diseases or conditions include those of the endocrine system, the reproductive organs, breast tissue, bone tissue, and the vascular system, especially those diseases that become more prevelant in aging males and females.
More specifically, such diseases and conditions include those selected from the group consisting of abnormal bone resorption, cardiovascular disease, cancer, metabolic disorders, and central nervous system disorders. Even more specifically, such diseases and conditions include those selected from the group consisting of osteoporosis, breast cancer, uterine cancer, ovarian cancer, prostate cancer, diabetes, and Alzheimer's disease.
WO 99112961 PCT/US981t 8577 EXAMPhES
The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention as many variations thereof are possible without departing from the spirit and scope of the invention.
Cloning and Sequencing of cDNA Clones of a Human Estrogen Receptor Gene The 5' rapid amplification of cDNA ends (R.ACE) product was identified by performing two rounds of polymerase chain reactions (PCR) on human testis Marathon-Ready cDNA (Clontech*product #?414-IS 1) using Venti'Polymerase (New England Biolabs product #254S). The first round of PCR was performed using the oligonucleotide, GGAGAAAGGTGCCCAGGTGTTGGCC (SEQ ID NO: 3), in the 5' coding region of human estrogen receptor beta (GenBanlf'sequence number X99101) and the Clontech*AP1 primer, according to the manufacturer s instructions. The second round of PCR was performed using either of two different nested primers having the sequences GTGGTCTGCCGACCAGGCCCACC (SEQ ID NO: 4) or GGTGTTGGCCACAACACATTTGG (SEQ ID NO: 5), corresponding to the 5' end of a human estrogen receptor beta clone (GenBank sequence 2~ number X99101), and the Clontech*AP2 primer, according to the manufacturer's. instructions. The PCR product was subcloned into the PCRAmpScript vector (Stratagene product # 211188) in JM109 E. coli.
This clone was sequenced on both strands by cycle sequencing (Pharmacia product #2?-1694-01), according to the manufacturer s instructions using primers corresponding to the vector sequence having the following sequence GTAATACGACTCACTATAGGGC (SEQ ID NO:
6) as well as a primer in the 5' end of the human estrogen receptor beta receptor gene having the following sequence GTTAGTGACATTGCTGGGAATGC (SEQ ID NO: ?). Further sequencing was performed with four additional primers having the * trade-mark _14_ WO 99ItZ961 PCT/US98118577 following sequences: GATCAGAGGCTTCAGCGAAACAG (SEQ ID
NO: 8), GAACGCGTGGATTAGTGACTAGCC (SEQ ID NO: 9), GGAGGAAGGAGAATTAAGGCTAG (SEQ ID NO: 10), and GAGATAACAGCTGAG.AAAACACC (SEQ LD NO: 11). These four primers were derived firona the initial sequence analysis. Sequence alignments and analysis of the nucleotide and protein sequences were carried out using MacVector and AssemblyLigri programs (Oxford Molecular Group) as well as the GCG Sequence Analysis Software Package (Madison, WI: pileup).
Cloning and Sequencing of Genomic DNA Clones of a Human Estrogen Receptor Gene To obtain a probe for use in the screening of a human genomic DNA library, cDNA was first generated from human testis mRNA
(Clontech product #6535-1) using an oligo-dT primer and MMLV
Reverse Transcriptase (Stratagene product #200420) according to the manufactures s instructions. The cDNA was amplified by PCR using Boehringer Mannheims Expand*High Fidelity PCR System (product #1 732 641) and two primers having the following sequences:
GTGATGAATTACAGCATTCCCAGCAATGTCACTAACTTGGAAGG
(SEQ ID N0:12) and ATGGCCCAAGCTTGGGTTCCAGTTCACCTCAGGGCCAGGCG (SEQ
ID NO: 13). The PCR product was cloned into the TGEM vector (Promega product #A3600) in JM109 E. coli. The product was sequenced on one strand with a Pharmacia cycle sequencing kit (product #27-1694-01) according to the manufacturer's instructions using nine primers having the following sequences: CTTGGAAGGTGGGCCTGGTCGGC
(SEQ ID NO: 14), GGAGAAAGGTGCCCAGGTGTTGGCC (SEQ ID NO:
15, wlrich is identical to SEQ ID NO: 3), CCGTTGCGCCAGCCCTGTTACTGG (SEQ ID NO: 16), CGCAAGAGCTGCCAGGCCTGCCG (SEQ ID NO: 17), CCCCGAGCAGCTAGTGCTCACCC (SEQ ID NO: 18), CTTGGAGAGCTGTTGGATGGAGG (SEQ ID NO: 19), * trade-_mark CTCTGTGTCAAGGCCATGATCC (SEQ ID NO: 20), CGTCAGGCATGCGAGTAACAAGGG (SEQ iD NO: 2I), and GCAAGTCCTCCATCACGGGGTCCG (SEQ ID NO: 22), corresponding to the published DNA sequence (Mosselman, S. et al., ER~B: identification and characterization of a noc~el human estrogen receptor, FEBS Letters, 392, pp. 49-53 [1996]). Sequence alignments and analysis of the nucleotide and protein sequences were carried out using MacVector and AssemblyLign programs (Oxford Molecular Group) as well as the GCG
Sequence Analysis Software Package (Madison, WI: pileup).
The cDNA clone obtained was digested with the restriction enzymes Ncol and KpnI to obtain an approximately 500 base pair fragment corresponding to the 5' end of the human estrogen receptor beta cDNA (GenBank sequence number X99101). This fragment was labeled with P-32 and used to screen a human genomic DNA library (Stratagene product #946206) as per the manufacturer's instructions.
One million bacteriophage plaques were screened and seventeen potential hybridizing phages were chosen. These phages were reamplified and screened using a slightly smaller probe (i.e an approximately 300 base pair fragment generated by digesting the human ERbeta clone with NcoI and PstI). Two positive phages were plaque purified and used for the production of DNA. The phages were digested with NotI and BamHI to generate smaller fragments encoding most of the phage DNA and these were subcloned into pBluescript~(Stratagene;
GenBank #52324). There were two fragments from one phage of approximately 8.5 and 6kb and two fragments from the other phage of approximately 7.7 and 6.3 kb. The genomic subclones of 8.5 and 7.7 kb were sequenced on both strands with a Pharmacia cycle sequencing Mt (product #27-1694-O1) according to the manufacturer s instructions using primers derived from the 5'RACE product sequencing (EXAMPLE
1). Sequence alignments and analysis of the nucleotide and protein sequences were carried out using MacVector and AssemblyLign programs (Oxford Molecular Group) as well as the GCG Sequence Analysis Soiiware Package (Madison, WI: pileup).
* trade-mark
It is another object of the present invention to provide ligands capable of binding to a novel estrogen receptor.
5 It is another object of the present invention to provide pharmaceutical compositions comprising ligands capable of binding to a novel estrogen receptor.
It is another object of the present invention to provide methods for treating and/or preventing estrogen receptor mediated diseases or 10 conditions.
These and other objects will become readily apparent from the detailed description which follows.
SUMMARY OF THE INVENTION
15 The present invention relates to an isolated estrogen receptor .
comprising the amino acid sequence of Figure 1 (which also corresponds to SEQ ID NO: 1 ).
In further embodiments, the present invention relates to an isolated estrogen receptor having an amino acid sequence that is 20 substantially similar to the amino acid sequence of Figure 1, wherein the estrogen receptor comprises at least 531 amino acids.
In further embodiments, the present invention relates to an isolated estrogen receptor comprising at least-531 amino acids and having substantially the same ligand binding properties or substantially 25 the same DNA binding properties as the estrogen receptor of Figure 1.
In further embodiments, the present invention relates to an isolated estrogen receptor that is derived from mammalian cells, preferably human cells.
In further embodiments, the present invention relates to an 30 isolated polynucleotide encoding the estrogen receptor having the amino acid sequence of Figure 1.
In further embodiments, the present invention relates to an isolated polynucleotide which is a DNA, a cDNA, or an RNA.
In further embodiments, the present invention relates to an 35 isolated polynucleotide which hydridizes to and is complementary to the CA 02323936 2000-11-20 ' a-WO 99112961 PCTlUS98I18577 polynucleotide encoding the estrogen receptor having the amino acid sequence of Figure 1.
In further embodiments, the present im~ention relates to an isolated polynucleotide comprising a polynucleotide encoding a mature polypeptide encoded by the estrogen receptor polynucleotide contained in an ATCC Deposit selected from the group consisting of ATCC Deposit No. 209238, ATCC Deposit No. 209239, and ATCC Deposit No. 209240.
In further embodiments, the present invention relates to an isolated polynucleotide comprising the nucleotide sequence of Figure 2 (which also corresponds to SEQ ID NO: 2).
In further embodiments, the present invention relates to an isolated polynucleotide which hybridizes to and is complementary to the polynucleotide of Figure 2, wherein said polynucleotide comprises at least 1593 nucleotides.
In further embodiments, the present invention relates to a vector containing the DNA.
In further embodiments, the present invention relates to a host cell transformed or transfected with the vector of the present invention.
In further embodiments, the present invention relates to a method for producing an estrogen receptor of the present invention.
In Further embodiments, the present invention relates to a method for determining whether a ligand can bind to the estrogen receptor of the present invention.
In further embodiments, the present invention relates to a ligand detected by the methods of the present invention.
In further embodiments, the present invention relates to a pharmaceutical composition comprising a ligand of the present invention.
In further embodiments, the present invention relates to a method for treating or preventing an estrogen receptor mediated disease or condition by administering an effective amount of a pharmaceutical composition of the present invention.
The deposits referred to herein will be maintained under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure. These deposits are provided merely as a convenience, The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, - are controlling in the event of any conflict with the description of the sequences herein. A
license may be required to make, use or sell the deposited materials, and no such license is hereby granted.
All percentages and ratios used herein, unless otherwise indicated, are by weight. The invention hereof can comprise, consist of, or consist essentially of the essential as well as optional ingredients, components, and methods described herein.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 shows the amino acid sequence of the estrogen receptor, i.e. the polypeptide, of the present invention.
FIG. 2 shows the nucleotide sequence, i.e. the cDNA
polynucleotide, encoding the estrogen receptor of the present invention.
This sequence includes the translation termination codon "TGA".
DESCRIPTION OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a polypeptide, namely an estrogen receptor, which has the deduced amino acid sequence of FIG. 1 or which has the amino acid sequence encoded by the cDNA of the clone deposited as ATCC Deposit No. 209238 on September 8, 1997, by the genomic DNA of the clone deposited as ATCC Deposit No. 209239 on September 8,1997, or by the genomic DNA of the clone deposited as ATCC Deposit No. 209240 on September 8, 1997. The present invention also relates to fragments, analogs and derivatives of such an estrogen receptor.
The terms "fragments", "derivatives", and "analogs " when referring to the estrogen receptor of FIG. 1 or that encoded by the deposited DNA, means a polypeptide which retains essentially the same biological function or activity as such estrogen receptor. Thus, an i analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature estrogen receptor.
The estrogen receptor of the present invention can be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide of the sequence of FIG. 1, or of that encoded by the deposited DNA. Also contemplated within the scope of the present invention are splice variants of the receptor of FIG. 1, or that encoded by the deposited DNA.
The fragments, derivatives, or analogs of the estrogen receptor of FIG. 1 or that encoded by the deposited DNA can be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue can be one that is or is not encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature estrogen receptor is fused with another compound, such as a compound to increase the half life of the estrogen receptor (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature estrogen receptor, such as a leader or secretory sequence or a sequence which is employed for purification of the mature estxogen receptor or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those sitilled in the art from the teachings herein.
The present invention also encompasses estrogen receptors which have substantially the same amino acid sequence as the estrogen receptor of Figure i. In further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 75% identical with the sequence shown in Figure 1.
In even further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 94°6 identical with the sequence shown in Figure 1. In even further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 95°.6 identical with the sequence shown in Figure 1. In even further embodiments of the present invention, the isolated estrogen receptor comprises at least 531 amino acid units and is at least about 99%
identical with the sequence shown in Figure 1.
The present invention also encompasses estrogen receptors comprising at least 531 amino acids and having substantially the same ligand binding proper~es or substantially the same DNA binding properties as that of the estrogen receptor of Figure 1. In other words, the respective ligand binding or DNA binding domains of the receptors have at least about 750, homology, preferably about 90°6 homology, more preferably about 95°.6 homology, and most preferably about 99°rb homology to each of the respective ligand binding and DNA binding domains in the receptor of Figure 1.
In accordance with another aspect of the present invention, there is provided an isolated nucleic acid, i.e. the polynucleotide, which encodes for the mature estrogen receptor having the deduced amino acid I S sequence of FIG. 1, or for the mature estrogen receptor encoded by the DNA of the deposited clones.
A polynucleotide encoding an estrogen receptor of the present invention can be obtained by performing polymerase chain reactions (PCR) on human testis cDNA and subcloning into a vector in JM109 E.
cola. Alternatively, the polynucleotide can be obtained by screening a human genomic DNA library derived from human testis.
The polynucleotide of the present invention can be in the form of RNA or in the form of DNA, which DNA includes eDNA, genomic DNA, and synthetic DNA. The DNA can be double-stranded or single-stranded, and if single stranded can be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature estrogen receptor can be identical to the coding sequence shown in FIG.
2 or that of the deposited clones or can be a different coding sequence, which coding sequence, as a result of redundancy or degeneracy of the genetic code, encodes the same, mature estrogen receptors as the DNA
of FIG. 2 or the deposited DNA.
The polynucleotide which encodes for the mature estrogen receptor of FIG. 1 or for the mature polypeptide encoded by the deposited DNA can include: only the coding sequence for the mature polypeptide;
the coding sequence for the mature polypeptide and additional coding _7_ sequence such as a leader or secretory sequence or a proprotein sequence; or the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequepce, such as introns or non-coding sequence ~' and/or 3' of the coding sequence for the mature polypeptide.
Thus, the term "polynucleotide encoding a polypeptide"
encompasses a polynucleotide which includes coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the polypeptide having the deduced amino acid sequence of FIG. 1 or the polypeptide encoded by the DNA of the deposited clones. The variant of the polynucleotide can be a naturally occurring allelic variant of the polynucleotide. The present invention also relates to polynucleotide probes constructed from the polynucleotide sequence of FIG. 2 or a segment of the sequence of FIG. 2 amplified by the PCR method, which can be utilized to screen a cDNA library to deduce the estrogen receptor of the present invention.
Thus, the present invention includes polynucleotides encoding the same mature estrogen receptor as shown in FIG. 1 or the same mature polypeptide encoded by the DNA of the deposited clones, as well as variants of such polynucleotides which variants encode for fragments, derivatives or analogs of the polypeptide of FIG. 2 or the polypeptide encoded by the DNA of the deposited clones. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.
As hereinabove indicated, the polynucleotide can have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in FIG. 2 or of the coding sequence of the deposited clones. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which can have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.
_g_ The present invention further relates to polynucleotides which hybridize to the polynucleotides encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 75°k complementary to the polynucleotide encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 90°~n complementary to the poiynucleotide encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 95°.~o complementary to the polynucleotide encoding the estrogen receptor having the amino acid sequence of FIG. 1. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 99% complementary to the polynucleotide encoding the estrogen receptor I S having the amino acid sequence of FIG. 1.
The present invention relates to an isolated polynucleotide comprising at least 1593 nucleotides. The present invention relates to an isolated polynucleotide comprising at least 1593 nucleotides which hybridizes to and is at least about 75°6 complementary to the polynucleotide of FIG. 2. The present invention relates to an isolated polynucleotide comprising at least 1593 nucleotides which hybridizes to and is at least about 90°r6 complementary to the polynucleotide of FIG.
2.
The present invention relates to an isolated polynucleotide comprising at Least 1593 nucleotides which hybridizes to and is at least about 95°.b 2S complementary to the polynucleotide of FIG. 2. The present invention relates to an isolated polynucleotide which hybridizes to and is at least about 9996 complementary to the poiynucleotide of FIG. 2.
The polynucleotides which hybridize to the hereinabove described polynucleotides encode estrogen receptors which retain substantially the same biological function or activity as the mature estrogen receptors encoded by the cDNA of FIG 2 or the deposited DNA. Hybridization is described in U.S. Patent No. 5,501,969, to Hastings et al., issued March 26, 1996.
The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.
The term "isolated' means that the material is removed from its S original environment (e.g., the natural environment if it is naturally-occuring). For example, a naturally-occuring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of estrogen receptors of the invention by recombinant techniques.
Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which can be, for example, a cloning vector or an expression vector. The vector can be, for example in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified for activating promoters, selecting transformants or amplifying the estrogen receptor genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
The polynucleotide of the present invention can be employed for producing a polypeptide by recombinant techniques. Thus, for example, the polynucleotide sequence can be included in any one of a variety of expression vehicles, in particular vectors or plasmids for expressing an estrogen receptor. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40: bacterial plasmids; phage DNA; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl, pox virus, and pseudorabies. However, any other plasmid or vector can be used as long as it is replicable and viable in the host.
As hereinabove indicated the appropriate DNA sequence can be inserted into the vector by a variety of procedures. In general, the DNA
sequence is inserted into appropriate restriction endonuclease sites by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
The present invention also includes recombinant constructs comprising one or more of the sequences as broadly defined herein. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.
In a further embodiment, the present invention relates to host cells containing the above-described construct. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Deatran mediated transfection, or electroporation lDavis, L., Dibner, M., Battey, L, Basic Methods in Molecular Biology, 1986) .
The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
Alternatively, the estrogen receptors of the present invention can be synthetically produced by conventional peptide synthesizers.
ll~Iature estrogen receptors can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters.
Cell-free translation systems can also be employed to produce such estrogen receptors using R.NAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor, NY, 1989).
CA 02323936 2000-11-20.
WO 99112961 PCT/US98lt 85??
The estrogen receptors of the present invention can be naturally purified products expressed from a high expressing cell line, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by 5 bacterial, yeast, higher plant, insect and mammalian cells in culture).
Alternatively, a baculovirus~nsect cell expression system can also be employed.
The estrogen receptors, their fragments or other derivatives or analogs thereof, or cells expressing them can be used as an immunogen IO to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain and humanized antibodies, as well as Fab fragments, or the product of a Fab expression library. Various procedures known in the art can be used for the production of such I S antibodies and fragments.
The present invention is also directed to ligands, i.e. drugs, of the estrogen receptors herein. The term "ligand" as used herein means any molecule which binds to the estrogen receptor of the present invention.
These ligands can have either agonist, partial agonist, antagonist, 20 partial antagonist, inverse agonist, or mixtures of these properties.
Thus, for example, a ligand that binds to an estrogen receptor of the present invention might modify, inhibit, or eliminate its function. In this way, the ligand can be used to treat or prevent a disease in which the estrogen receptor is involved. The ligands contemplated herein are 25 those that have selectivity to specifically activate or inhibit genes that are normally regulated by the estrogen receptors of the present invention.
The present invention also relates to methods for determining whether a ligand not Down to be capable of binding to a human estrogen receptor can bind to a human estrogen receptor. These 30 methods comprise contacting a mammalian cell comprising an isolated DNA molecule encoding a human estrogen receptor with the ligand under conditions permitting binding of ligands known to bind to an estrogen receptor, detecting the presence of any of the ligand bound to a human estrogen receptor, and thereby determining whether the ligand 35 binds to a human estrogen receptor. In these methods, the mammalian I~
cell is actually expressing the isolated DNA molecules. The general methodology for conducting such a method is well known to those of ordinary skill in the art. See EP 787,797, to Weinshank et al., published July 6, 1997..
Alternatively, RNA that ultimately encodes for the estrogen receptor could be injected into, for example Xenopus oocytes, and expressed, and used in analogous assay experiments.
The present invention also relates to pharmaceutical compositions comprising the ligands of the present invention. Such compositions comprise a pharmaceutically effective amount of the ligand. The term "pharmaceutically effective amount", as used herein, means that amount of the ligand that will elicit the desired therapeutic effect or response when administered in accordance with the desired treatment regimen. The ligand is typically administered in admixture with IS suitable pharmaceutical diluents, excipients, or carriers, collectively referred to herein as "carrier materials", suitably selected with respect to the mode of administration, i.e. oral, LV., nasal, parenteral, ocular, etc. A wide variety of product and dosage forms well known to one of ordinary skill in the art ca.n be used to administer these ligands.
The present invention also relates to methods for treating and/or preventing estrogen receptor mediated diseases or conditions. By "estrogen receptor mediated diseases or conditions" is meant a physiological or pathological state in which an estrogen receptor is involved. Nonlimiting examples of estrogen receptor mediated diseases or conditions include those of the endocrine system, the reproductive organs, breast tissue, bone tissue, and the vascular system, especially those diseases that become more prevelant in aging males and females.
More specifically, such diseases and conditions include those selected from the group consisting of abnormal bone resorption, cardiovascular disease, cancer, metabolic disorders, and central nervous system disorders. Even more specifically, such diseases and conditions include those selected from the group consisting of osteoporosis, breast cancer, uterine cancer, ovarian cancer, prostate cancer, diabetes, and Alzheimer's disease.
WO 99112961 PCT/US981t 8577 EXAMPhES
The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention as many variations thereof are possible without departing from the spirit and scope of the invention.
Cloning and Sequencing of cDNA Clones of a Human Estrogen Receptor Gene The 5' rapid amplification of cDNA ends (R.ACE) product was identified by performing two rounds of polymerase chain reactions (PCR) on human testis Marathon-Ready cDNA (Clontech*product #?414-IS 1) using Venti'Polymerase (New England Biolabs product #254S). The first round of PCR was performed using the oligonucleotide, GGAGAAAGGTGCCCAGGTGTTGGCC (SEQ ID NO: 3), in the 5' coding region of human estrogen receptor beta (GenBanlf'sequence number X99101) and the Clontech*AP1 primer, according to the manufacturer s instructions. The second round of PCR was performed using either of two different nested primers having the sequences GTGGTCTGCCGACCAGGCCCACC (SEQ ID NO: 4) or GGTGTTGGCCACAACACATTTGG (SEQ ID NO: 5), corresponding to the 5' end of a human estrogen receptor beta clone (GenBank sequence 2~ number X99101), and the Clontech*AP2 primer, according to the manufacturer's. instructions. The PCR product was subcloned into the PCRAmpScript vector (Stratagene product # 211188) in JM109 E. coli.
This clone was sequenced on both strands by cycle sequencing (Pharmacia product #2?-1694-01), according to the manufacturer s instructions using primers corresponding to the vector sequence having the following sequence GTAATACGACTCACTATAGGGC (SEQ ID NO:
6) as well as a primer in the 5' end of the human estrogen receptor beta receptor gene having the following sequence GTTAGTGACATTGCTGGGAATGC (SEQ ID NO: ?). Further sequencing was performed with four additional primers having the * trade-mark _14_ WO 99ItZ961 PCT/US98118577 following sequences: GATCAGAGGCTTCAGCGAAACAG (SEQ ID
NO: 8), GAACGCGTGGATTAGTGACTAGCC (SEQ ID NO: 9), GGAGGAAGGAGAATTAAGGCTAG (SEQ ID NO: 10), and GAGATAACAGCTGAG.AAAACACC (SEQ LD NO: 11). These four primers were derived firona the initial sequence analysis. Sequence alignments and analysis of the nucleotide and protein sequences were carried out using MacVector and AssemblyLigri programs (Oxford Molecular Group) as well as the GCG Sequence Analysis Software Package (Madison, WI: pileup).
Cloning and Sequencing of Genomic DNA Clones of a Human Estrogen Receptor Gene To obtain a probe for use in the screening of a human genomic DNA library, cDNA was first generated from human testis mRNA
(Clontech product #6535-1) using an oligo-dT primer and MMLV
Reverse Transcriptase (Stratagene product #200420) according to the manufactures s instructions. The cDNA was amplified by PCR using Boehringer Mannheims Expand*High Fidelity PCR System (product #1 732 641) and two primers having the following sequences:
GTGATGAATTACAGCATTCCCAGCAATGTCACTAACTTGGAAGG
(SEQ ID N0:12) and ATGGCCCAAGCTTGGGTTCCAGTTCACCTCAGGGCCAGGCG (SEQ
ID NO: 13). The PCR product was cloned into the TGEM vector (Promega product #A3600) in JM109 E. coli. The product was sequenced on one strand with a Pharmacia cycle sequencing kit (product #27-1694-01) according to the manufacturer's instructions using nine primers having the following sequences: CTTGGAAGGTGGGCCTGGTCGGC
(SEQ ID NO: 14), GGAGAAAGGTGCCCAGGTGTTGGCC (SEQ ID NO:
15, wlrich is identical to SEQ ID NO: 3), CCGTTGCGCCAGCCCTGTTACTGG (SEQ ID NO: 16), CGCAAGAGCTGCCAGGCCTGCCG (SEQ ID NO: 17), CCCCGAGCAGCTAGTGCTCACCC (SEQ ID NO: 18), CTTGGAGAGCTGTTGGATGGAGG (SEQ ID NO: 19), * trade-_mark CTCTGTGTCAAGGCCATGATCC (SEQ ID NO: 20), CGTCAGGCATGCGAGTAACAAGGG (SEQ iD NO: 2I), and GCAAGTCCTCCATCACGGGGTCCG (SEQ ID NO: 22), corresponding to the published DNA sequence (Mosselman, S. et al., ER~B: identification and characterization of a noc~el human estrogen receptor, FEBS Letters, 392, pp. 49-53 [1996]). Sequence alignments and analysis of the nucleotide and protein sequences were carried out using MacVector and AssemblyLign programs (Oxford Molecular Group) as well as the GCG
Sequence Analysis Software Package (Madison, WI: pileup).
The cDNA clone obtained was digested with the restriction enzymes Ncol and KpnI to obtain an approximately 500 base pair fragment corresponding to the 5' end of the human estrogen receptor beta cDNA (GenBank sequence number X99101). This fragment was labeled with P-32 and used to screen a human genomic DNA library (Stratagene product #946206) as per the manufacturer's instructions.
One million bacteriophage plaques were screened and seventeen potential hybridizing phages were chosen. These phages were reamplified and screened using a slightly smaller probe (i.e an approximately 300 base pair fragment generated by digesting the human ERbeta clone with NcoI and PstI). Two positive phages were plaque purified and used for the production of DNA. The phages were digested with NotI and BamHI to generate smaller fragments encoding most of the phage DNA and these were subcloned into pBluescript~(Stratagene;
GenBank #52324). There were two fragments from one phage of approximately 8.5 and 6kb and two fragments from the other phage of approximately 7.7 and 6.3 kb. The genomic subclones of 8.5 and 7.7 kb were sequenced on both strands with a Pharmacia cycle sequencing Mt (product #27-1694-O1) according to the manufacturer s instructions using primers derived from the 5'RACE product sequencing (EXAMPLE
1). Sequence alignments and analysis of the nucleotide and protein sequences were carried out using MacVector and AssemblyLign programs (Oxford Molecular Group) as well as the GCG Sequence Analysis Soiiware Package (Madison, WI: pileup).
* trade-mark
Claims (19)
1. An isolated estrogen receptor having an amino acid sequence that is at least about 90% identical with the sequence shown in Figure 1, wherein said estrogen receptor comprises at least 531 amino acids.
2. An isolated estrogen receptor having an amino acid sequence that is at least about 75% identical with the sequence shown in Figure 1, wherein said estrogen receptor comprises at least 531 amino acids.
3. An isolated estrogen receptor comprising at least 531 amino acids having substantially the same ligand binding properties as that of the estrogen receptor SEQ. ID No: 1.
4. An isolated estrogen receptor comprising at least 531 amino acids having substantially the same DNA binding properties at that of the estrogen receptor SEQ. ID No: 1.
5. An isolated polynucleotide comprising a polynucleotide encoding a mature polypeptide encoded by the estrogen receptor polynucleotide contained in an ATCC Deposit selected from the group consisting of ATCC Deposit No. 209238, ATCC Deposit No.
209239, and ATCC Deposit No. 209240.
209239, and ATCC Deposit No. 209240.
6. A vector containing a DNA polynucleotide encoding the estrogen receptor having the amino acid sequence of SEQ. ID No: 1.
7. A host cell transformed or transfected with the vector of Claim 6.
8. A method for producing an estrogen receptor comprising:
expressing from the host cell of Claim 7 the estrogen receptor encoded by said DNA.
expressing from the host cell of Claim 7 the estrogen receptor encoded by said DNA.
9. A method for determining whether a ligand not known to be capable of binding to a human estrogen receptor can bind to a human estrogen receptor, said method comprising:
(a) contacting a mammalian cell, comprising an isolated DNA molecule encoding a human estrogen receptor having the amino acid sequence of SEQ.
ID No: 1, with the ligand under conditions permitting binding of ligands known to bind to an estrogen receptor, (b) detecting the presence of any of the ligand bound to a human estrogen receptor, and (c) determining whether the ligand binds to a human estrogen receptor.
(a) contacting a mammalian cell, comprising an isolated DNA molecule encoding a human estrogen receptor having the amino acid sequence of SEQ.
ID No: 1, with the ligand under conditions permitting binding of ligands known to bind to an estrogen receptor, (b) detecting the presence of any of the ligand bound to a human estrogen receptor, and (c) determining whether the ligand binds to a human estrogen receptor.
10. A ligand detected by the method of Claim 9.
11. A pharmaceutical composition comprising:
(a) a ligand identified by the method of Claim 9, and (b) a pharmaceutically acceptable carrier.
(a) a ligand identified by the method of Claim 9, and (b) a pharmaceutically acceptable carrier.
12. A method for treating or preventing an estrogen receptor mediated disease or condition, said method comprising administering an effective amount of a pharmaceutical composition according to Claim 11.
13. A method according to Claim 12 wherein said estrogen receptor mediated disease or condition is selected from the group consisting of abnormal bone resorption, cardiovascular diseases, cancer, metabolic disorders, or central nervous system disorders.
14. A method according to Claim 12 wherein said estrogen receptor mediated disease or condition is osteoporosis.
15. A method according to Claim 12 wherein said estrogen receptor mediated disease or condition is selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, prostate cancer, diabetes, or Alzheimer's disease.
16. Use of a ligand detected by the method of Claim 9 for the preparation of a medicament for the treatment or prevention of an estrogen receptor mediated disease or condition.
17. The use of Claim 16, wherein said estrogen receptor mediated disease or condition is selected from the group consisting of abnormal bone resorption, cardiovascular diseases, cancer, metabolic disorders or central nervous system disorders.
18. The use of Claim 16, wherein said estrogen receptor mediated disease or condition is osteoporosis.
19. The use of Claim 16, wherein said estrogen receptor mediated disease or condition is selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, prostate cancer, diabetes, or Alzheimer's disease.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5827197P | 1997-09-08 | 1997-09-08 | |
| US60/058,271 | 1997-09-08 | ||
| US6052097P | 1997-09-30 | 1997-09-30 | |
| US60/060,520 | 1997-09-30 | ||
| GB9722884.5 | 1997-10-30 | ||
| GBGB9722884.5A GB9722884D0 (en) | 1997-10-30 | 1997-10-30 | Estrogen receptor |
| GBGB9806032.0A GB9806032D0 (en) | 1998-03-20 | 1998-03-20 | Estrogen receptor |
| GB9806032.0 | 1998-03-20 | ||
| CA002302629A CA2302629C (en) | 1997-09-08 | 1998-09-04 | Estrogen receptor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002302629A Division CA2302629C (en) | 1997-09-08 | 1998-09-04 | Estrogen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2323936A1 true CA2323936A1 (en) | 1999-03-18 |
Family
ID=27508722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002323936A Abandoned CA2323936A1 (en) | 1997-09-08 | 1998-09-04 | Estrogen receptor |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2323936A1 (en) |
-
1998
- 1998-09-04 CA CA002323936A patent/CA2323936A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU226073B1 (en) | Neurotrophic growth factor | |
| WO1996004396A1 (en) | Neural cell adhesion molecules, nucleotide sequences encoding the molecules, and methods of use thereof | |
| EP0975752A1 (en) | Human cerberus protein | |
| US20020160451A1 (en) | Novel orphan receptors | |
| WO1998007736A9 (en) | Don-1 gene and polypeptides and uses therefor | |
| AU4154097A (en) | Don-1 gene and polypeptides and uses therefor | |
| WO1996018651A1 (en) | Human somatostatin-like receptor | |
| WO1994011501A1 (en) | cDNAs ENCODING HUMAN NMDA-22A RECEPTOR SUBUNIT AND ISOFORMS OF THE HUMAN NMDA-R1 RECEPTOR SUBUNIT, TRANSFECTED CELL LINE EXPRESSING THEM | |
| US6222015B1 (en) | Estrogen receptor | |
| KR100676229B1 (en) | Neurotrophic factor receptor | |
| EP1012177B1 (en) | Estrogen receptor | |
| WO2000055193A2 (en) | Human dan/cerberus related protein 6 (dcr6) | |
| CA2323936A1 (en) | Estrogen receptor | |
| US6835381B1 (en) | Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor | |
| AU753400C (en) | Orphan receptors | |
| US6207413B1 (en) | Nucleic acids encoding novel orphan cytokine receptors | |
| AU754446B2 (en) | Novel NPY family member | |
| CA2377788A1 (en) | Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |